326 related articles for article (PubMed ID: 16443396)
1. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells.
Gonçalves MA; Holkers M; Cudré-Mauroux C; van Nierop GP; Knaän-Shanzer S; van der Velde I; Valerio D; de Vries AA
Mol Ther; 2006 May; 13(5):976-86. PubMed ID: 16443396
[TBL] [Abstract][Full Text] [Related]
2. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability.
Gonçalves MA; van Nierop GP; Tijssen MR; Lefesvre P; Knaän-Shanzer S; van der Velde I; van Bekkum DW; Valerio D; de Vries AA
J Virol; 2005 Mar; 79(5):3146-62. PubMed ID: 15709034
[TBL] [Abstract][Full Text] [Related]
3. Human mesenchymal stem cells ectopically expressing full-length dystrophin can complement Duchenne muscular dystrophy myotubes by cell fusion.
Gonçalves MA; de Vries AA; Holkers M; van de Watering MJ; van der Velde I; van Nierop GP; Valerio D; Knaän-Shanzer S
Hum Mol Genet; 2006 Jan; 15(2):213-21. PubMed ID: 16321987
[TBL] [Abstract][Full Text] [Related]
4. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
5. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
Athanasopoulos T; Graham IR; Foster H; Dickson G
Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
[TBL] [Abstract][Full Text] [Related]
6. Progress toward gene therapy of Duchenne muscular dystrophy.
Hartigan-O'Connor D; Chamberlain JS
Semin Neurol; 1999; 19(3):323-32. PubMed ID: 12194388
[TBL] [Abstract][Full Text] [Related]
7. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy.
Lai Y; Li D; Yue Y; Duan D
Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629
[TBL] [Abstract][Full Text] [Related]
8. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
Bilbao R; Reay DP; Wu E; Zheng H; Biermann V; Kochanek S; Clemens PR
Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
[TBL] [Abstract][Full Text] [Related]
9. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
[TBL] [Abstract][Full Text] [Related]
10. Stable transduction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors.
Gonçalves MA; van der Velde I; Knaän-Shanzer S; Valerio D; de Vries AA
Virology; 2004 Apr; 321(2):287-96. PubMed ID: 15051388
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle.
Akkaraju GR; Huard J; Hoffman EP; Goins WF; Pruchnic R; Watkins SC; Cohen JB; Glorioso JC
J Gene Med; 1999; 1(4):280-9. PubMed ID: 10738561
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.
Blankinship MJ; Gregorevic P; Chamberlain JS
Mol Ther; 2006 Feb; 13(2):241-9. PubMed ID: 16361117
[TBL] [Abstract][Full Text] [Related]
13. Dystrophin expression in host muscle following transplantation of muscle precursor cells modified with the phiC31 integrase.
Quenneville SP; Chapdelaine P; Rousseau J; Tremblay JP
Gene Ther; 2007 Mar; 14(6):514-22. PubMed ID: 17167499
[TBL] [Abstract][Full Text] [Related]
14. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype.
Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S
Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500
[TBL] [Abstract][Full Text] [Related]
15. Full-length dystrophin gene transfer to the mdx mouse in utero.
Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
[TBL] [Abstract][Full Text] [Related]
16. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
[TBL] [Abstract][Full Text] [Related]
17. Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade.
Jiang Z; Schiedner G; van Rooijen N; Liu CC; Kochanek S; Clemens PR
Mol Ther; 2004 Oct; 10(4):688-96. PubMed ID: 15451453
[TBL] [Abstract][Full Text] [Related]
18. Successful transplantation of genetically corrected DMD myoblasts following ex vivo transduction with the dystrophin minigene.
Moisset PA; Skuk D; Asselin I; Goulet M; Roy B; Karpati G; Tremblay JP
Biochem Biophys Res Commun; 1998 Jun; 247(1):94-9. PubMed ID: 9636661
[TBL] [Abstract][Full Text] [Related]
19. Site-specific integration of a transgene mediated by a hybrid adenovirus/adeno-associated virus vector using the Cre/loxP-expression-switching system.
Ueno T; Matsumura H; Tanaka K; Iwasaki T; Ueno M; Fujinaga K; Asada K; Kato I
Biochem Biophys Res Commun; 2000 Jul; 273(2):473-8. PubMed ID: 10873630
[TBL] [Abstract][Full Text] [Related]
20. The future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene.
Roberts M; Dickson G
Curr Opin Mol Ther; 2002 Aug; 4(4):343-8. PubMed ID: 12222872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
